Myocardial oxygen metabolism improvement

The phrase "myocardial oxygen metabolism improvement" refers to interventions and mechanisms that enhance the delivery, extraction, or utilization of oxygen by cardiac muscle (myocardium). This process is governed by physiological parameters such as heart rate, contractility, coronary blood flow, and arterial oxygen content, but is not a single molecule or receptor. Therapeutic approaches that aim to improve myocardial oxygen metabolism may include drugs influencing coronary vasodilation (via adenosine, nitric oxide, prostaglandins, β-adrenoceptors), modulation of heart rate and contractility, and optimizing hemoglobin and red blood cell concentration. However, none of these are unified under a single molecular target called "myocardial oxygen metabolism improvement"; rather, multiple targets and pathways contribute to this physiological outcome. The underlying molecular mechanisms include regulation of coronary blood flow predominantly via vasodilation, metabolic feedback (adenosine hypothesis), sympathetic control, and mitochondrial respiration. Disease relevance includes cardiovascular diseases such as ischemic heart disease, myocardial infarction, and heart failure, where oxygen delivery and utilization by the myocardium are critically impaired. Drugs that can affect myocardial oxygen metabolism include β-blockers (lower heart rate/contractility), nitrates (increase blood flow), calcium channel blockers, and agents improving hemoglobin levels, but again, these act through distinct targets and mechanisms. In summary, "myocardial oxygen metabolism improvement" is a therapeutic goal and physiological process, not a molecular target or receptor. Therefore, it should not be treated or structured as a canonical molecular entity for target-based drug discovery or characterization.

Therapeutic approaches achieve myocardial oxygen metabolism improvement by influencing physiological parameters. These include drugs influencing coronary vasodilation (via adenosine, nitric oxide, prostaglandins, β-adrenoceptors), modulation of heart rate and contractility, and optimizing hemoglobin and red blood cell concentration.